SUBSCRIBE
SUBSCRIBE
News   Policy

UK’s NICE Turns Down GlaxoSmithKline’s Tyverb Offer

October 14, 2008 | 
1 min read
LONDON, Oct 14 (Reuters) - Britain's healthcare cost effectiveness watchdog NICE has rebuffed GlaxoSmithKline's latest bid to get its drug Tyverb - for women with advanced breast cancer - into the state health system, the company said on Tuesday.
Regulatory Europe
GSK
MORE ON THIS TOPIC
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
FDA
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
August 12, 2026
 · 
1 min read
 · 
Jef Akst
Cross icon. Reject, decline concept. Hand Mouse Cursor Clicks the Button. Pointer Push Press
Manufacturing
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
August 11, 2026
 · 
1 min read
 · 
Gabrielle Masson